0000899243-20-025694.txt : 20200918
0000899243-20-025694.hdr.sgml : 20200918
20200918160608
ACCESSION NUMBER: 0000899243-20-025694
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200917
FILED AS OF DATE: 20200918
DATE AS OF CHANGE: 20200918
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fox Jonathan C
CENTRAL INDEX KEY: 0001655016
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38533
FILM NUMBER: 201184080
MAIL ADDRESS:
STREET 1: C/O MYOKARDIA, INC.
STREET 2: 333 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eidos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001731831
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463733671
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 650-391-9740
MAIL ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-17
0
0001731831
Eidos Therapeutics, Inc.
EIDX
0001655016
Fox Jonathan C
C/O EIDOS THERAPEUTICS, INC.
101 MONTGOMERY STREET, SUITE 2000
SAN FRANCISCO
CA
94104
0
1
0
0
See Remarks
Common Stock
2020-09-17
4
S
0
5767
50.1576
D
377673
I
See footnote
Common Stock
3294
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020.
Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.46 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014.
President and Chief Medical Officer
/s/ Franco Valle, as Attorney-in-Fact
2020-09-17